Aminobenzoic Acid Derivative

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 30 Experts worldwide ranked by ideXlab platform

Michael Wiese - One of the best experts on this subject based on the ideXlab platform.

  • a 4 Aminobenzoic Acid Derivative as novel lead for selective inhibitors of multidrug resistance associated proteins
    Bioorganic & Medicinal Chemistry Letters, 2008
    Co-Authors: Stefan Leyers, Hansgeorg Hacker, Jeanette Wiendlocha, Michael Gutschow, Michael Wiese
    Abstract:

    We present a novel lead for inhibitors of multidrug resistance-associated proteins (MRPs). Compound 1 (4-[(5,6,7,8-tetrahydro-4-oxo-4H-[1]benzothieno[2,3-d][1,3]thiazin-2-yl)amino]benzoic Acid) was about six times more potent than the known inhibitor MK571 at MRP1, while at MRP2 its effect was similar to that of MK571. Structural analogs were also evaluated. Among them, compound 2, sharing the 4-Aminobenzoic Acid substructure with 1, also inhibited MRP1. Both Derivatives were inactive against P-gp. It can be concluded that their carboxyl group is needed for inhibition of MRPs and accounts for the selectivity of these compounds.

Stefan Leyers - One of the best experts on this subject based on the ideXlab platform.

  • a 4 Aminobenzoic Acid Derivative as novel lead for selective inhibitors of multidrug resistance associated proteins
    Bioorganic & Medicinal Chemistry Letters, 2008
    Co-Authors: Stefan Leyers, Hansgeorg Hacker, Jeanette Wiendlocha, Michael Gutschow, Michael Wiese
    Abstract:

    We present a novel lead for inhibitors of multidrug resistance-associated proteins (MRPs). Compound 1 (4-[(5,6,7,8-tetrahydro-4-oxo-4H-[1]benzothieno[2,3-d][1,3]thiazin-2-yl)amino]benzoic Acid) was about six times more potent than the known inhibitor MK571 at MRP1, while at MRP2 its effect was similar to that of MK571. Structural analogs were also evaluated. Among them, compound 2, sharing the 4-Aminobenzoic Acid substructure with 1, also inhibited MRP1. Both Derivatives were inactive against P-gp. It can be concluded that their carboxyl group is needed for inhibition of MRPs and accounts for the selectivity of these compounds.

Michael Gutschow - One of the best experts on this subject based on the ideXlab platform.

  • a 4 Aminobenzoic Acid Derivative as novel lead for selective inhibitors of multidrug resistance associated proteins
    Bioorganic & Medicinal Chemistry Letters, 2008
    Co-Authors: Stefan Leyers, Hansgeorg Hacker, Jeanette Wiendlocha, Michael Gutschow, Michael Wiese
    Abstract:

    We present a novel lead for inhibitors of multidrug resistance-associated proteins (MRPs). Compound 1 (4-[(5,6,7,8-tetrahydro-4-oxo-4H-[1]benzothieno[2,3-d][1,3]thiazin-2-yl)amino]benzoic Acid) was about six times more potent than the known inhibitor MK571 at MRP1, while at MRP2 its effect was similar to that of MK571. Structural analogs were also evaluated. Among them, compound 2, sharing the 4-Aminobenzoic Acid substructure with 1, also inhibited MRP1. Both Derivatives were inactive against P-gp. It can be concluded that their carboxyl group is needed for inhibition of MRPs and accounts for the selectivity of these compounds.

Jeanette Wiendlocha - One of the best experts on this subject based on the ideXlab platform.

  • a 4 Aminobenzoic Acid Derivative as novel lead for selective inhibitors of multidrug resistance associated proteins
    Bioorganic & Medicinal Chemistry Letters, 2008
    Co-Authors: Stefan Leyers, Hansgeorg Hacker, Jeanette Wiendlocha, Michael Gutschow, Michael Wiese
    Abstract:

    We present a novel lead for inhibitors of multidrug resistance-associated proteins (MRPs). Compound 1 (4-[(5,6,7,8-tetrahydro-4-oxo-4H-[1]benzothieno[2,3-d][1,3]thiazin-2-yl)amino]benzoic Acid) was about six times more potent than the known inhibitor MK571 at MRP1, while at MRP2 its effect was similar to that of MK571. Structural analogs were also evaluated. Among them, compound 2, sharing the 4-Aminobenzoic Acid substructure with 1, also inhibited MRP1. Both Derivatives were inactive against P-gp. It can be concluded that their carboxyl group is needed for inhibition of MRPs and accounts for the selectivity of these compounds.

Hansgeorg Hacker - One of the best experts on this subject based on the ideXlab platform.

  • a 4 Aminobenzoic Acid Derivative as novel lead for selective inhibitors of multidrug resistance associated proteins
    Bioorganic & Medicinal Chemistry Letters, 2008
    Co-Authors: Stefan Leyers, Hansgeorg Hacker, Jeanette Wiendlocha, Michael Gutschow, Michael Wiese
    Abstract:

    We present a novel lead for inhibitors of multidrug resistance-associated proteins (MRPs). Compound 1 (4-[(5,6,7,8-tetrahydro-4-oxo-4H-[1]benzothieno[2,3-d][1,3]thiazin-2-yl)amino]benzoic Acid) was about six times more potent than the known inhibitor MK571 at MRP1, while at MRP2 its effect was similar to that of MK571. Structural analogs were also evaluated. Among them, compound 2, sharing the 4-Aminobenzoic Acid substructure with 1, also inhibited MRP1. Both Derivatives were inactive against P-gp. It can be concluded that their carboxyl group is needed for inhibition of MRPs and accounts for the selectivity of these compounds.